Ionis Pharmaceuticals, Inc. is a biotechnology company specializing in the discovery, development, and commercialization of human therapeutics using antisense technology. This proprietary platform ena... Ionis Pharmaceuticals, Inc. is a biotechnology company specializing in the discovery, development, and commercialization of human therapeutics using antisense technology. This proprietary platform enables the creation of novel drugs targeting difficult-to-treat diseases across cardiovascular, metabolic, neurological, and rare disease areas. Key marketed products include TRYNGOLZA (olezarsen), the first FDA-approved treatment for adults with familial chylomicronemia syndrome as an adjunct to diet; DAWNZERA (donidalorsen), an RNA-targeted prophylactic therapy for hereditary angioedema in patients 12 years and older; and royalties from partnered drugs such as SPINRAZA (nusinersen) for spinal muscular atrophy, WAINUA (eplontersen) for polyneuropathy of hereditary transthyretin-mediated amyloidosis, Qalsody for ALS, Tegsedi, and Waylivra. Ionis maintains a broad pipeline of investigational medicines, including olezarsen for severely elevated triglycerides, zilganersen for Alexander disease, bepirovirsen for chronic hepatitis B, ulefnersen for FUS-ALS, sapablursen for polycythemia vera, and opemalirsen for APOL1-mediated kidney disease. The company generates revenues from product sales, royalties, and R&D collaborations with partners like Biogen and AstraZeneca. Founded in 1989 and headquartered in Carlsbad, California, Ionis Pharmaceuticals plays a pivotal role in advancing RNA-targeted therapies for unmet medical needs.Show lessShow more

Disclosures ESG Data Financial Data

GHG Emissions Climate Targets EU Taxonomy Energy Waste Management

Data not available

Ionis Pharmaceuticals is not subject to EU Taxonomy reporting

Based on current regulatory requirements, Ionis Pharmaceuticals is not required to report EU Taxonomy data under the CSRD framework. As a result, we have not conducted a detailed EU Taxonomy data review for this company.

If you believe this assessment should be revisited, you may submit a data coverage request and our team will review the company's regulatory applicability.

Would you like us to review Ionis Pharmaceuticals's data?

Start your 30-day free trial to request a data review for Ionis Pharmaceuticals.

Start Free Trial

Legal Center Contact Us

Ionis Pharmaceuticals Inc

Ionis Pharmaceuticals is not subject to EU Taxonomy reporting

Account Restricted